findmyKOL
Clinical trialNCT04563507RecruitingPhase 2Interventional

Combined Immunotherapies in Metastatic ER+ Breast Cancer

SponsorWeill Medical College of Cornell UniversityEnrollment102Breast Cancer
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Brooklyn Methodist Hospital - Newyork Presbyterian

    New York, New York, United States

    Hani Ashamalla, M.D.
    Recruiting
  • New York Presbyterian Hospital - Queens

    New York, New York, United States

    Akkamma Ravi, M.D.Silvia Formenti, M.D.
    Recruiting
  • Weill Cornell Medicine

    New York, New York, United States

    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
12 Nov 2020
Primary completion
31 Oct 2027
Completion
31 Oct 2028
Last update posted
15 Dec 2025
Registered enrollment
102
Registry id
NCT04563507

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.